United Therapeutics Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Martine A. Rothblatt
- Full Time Employees
- 1,400
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1040 Spring Street Silver Spring MD United States of America 20910
- IPO Date
- Jun 17, 1999
- CIK
- 0001082554
- Website
- unither.com
- Similar Companies
- Business
- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit biotechnology company founded in 1996 and headquartered in Silver Spring, Maryland, with co-headquarters in Research Triangle Park, North Carolina, develops and commercializes innovative products to address unmet medical needs of patients with chronic and life-threatening diseases, particularly pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), high-risk neuroblastoma, and organ failure; its core commercial portfolio includes Tyvaso DPI and Tyvaso, inhaled formulations of treprostinil via dry powder inhaler and nebulizer for PAH and other lung conditions; Remodulin (treprostinil) injection and Orenitram (treprostinil extended-release tablets) for PAH to improve exercise capacity and delay disease progression; Adcirca (tadalafil), an oral PDE-5 inhibitor for PAH; Unituxin (dinutuximab) injection, a monoclonal antibody for pediatric high-risk neuroblastoma; and Remunity Pump, a subcutaneous delivery system for Remodulin. The company operates in the United States, Canada, Central and South America, Europe, the Middle East, and Asia through distribution partners and maintains manufacturing facilities in locations including Melbourne and Jacksonville, Florida; Blacksburg, Virginia; Manchester, New Hampshire; and Magog and Bromont, Quebec. United Therapeutics targets patients with cardiovascular, pulmonary, oncology, and organ transplant needs, while advancing a pipeline featuring RemoPro and ralinepag for PAH, Aurora-GT gene therapy for lung vascular rebuilding, nebulized Tyvaso for IPF, and xenotransplantation technologies including UKidney for end-stage renal disease via xenografts, allogenic recellularization, and bioprinting. In recent developments, United Therapeutics announced the first human transplant in its EXPAND clinical trial of UKidney for end-stage renal disease in November 2025, marking a milestone in xenotransplantation; the company reported positive top-line results from the phase 3 TETON-2 pivotal study of nebulized Tyvaso in IPF in September 2025, meeting the primary endpoint and key secondary measures across subgroups; it initiated a $1 billion accelerated share repurchase program in August 2025 with Citibank to return capital to shareholders while supporting growth; and earlier acquired IVEVA and MiroMatrix to bolster organ manufacturing expertise, alongside investments in new manufacturing facilities and designated pathogen-free sites.
Company News
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR
Freestone Grove Partners LP Acquires New Stake in United Therapeutics Corporation $UTHR
Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
Allworth Financial LP Invests $632,000 in United Therapeutics Corporation $UTHR
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares
Atwood & Palmer Inc. Sells 957 Shares of United Therapeutics Corporation $UTHR
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
United Therapeutics Q2 Earnings Call Highlights
United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript
United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say
United Therapeutics (UTHR) Q2 Earnings Surpass Estimates
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results